NCT07469202 2026-03-13
CYTALUX Dose Extension Study
On Target Laboratories, LLC
Phase 4 Not yet recruiting
Clinical Trials
4 trialsNCT04941378 2022-06-27
OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT02317705 2022-06-21
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
On Target Laboratories, LLC
Phase 2 Completed
NCT03180307 2022-02-04
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
On Target Laboratories, LLC
Phase 3 Completed